AstraZeneca (AZN) announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of its PD-L1 inhibitor Imfinzi (durvalumab) as a treatment for certain patients with primary advanced or recurrent endometrial cancer.The CHMP recommended the approval of Imfinzi plus chemotherapy, followed by Imfinzi and Lynparza as a first-line treatment for patients with mismatch repair proficient (pMMR) advanced or recurrent endometrial cancer.The CHMP ...